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 2 
 Abstract  
 Different polyphenol compounds are ingested when consuming a serving of fruits rich in 
polyphenols, spanning from one-phenol hydroxybenzoic acid to more complex polymeric 
compounds. Only a minor quantity of the polyphenols (5-10%) is absorbed. The remainder 
reaches the colon and is extensively metabolized by gut microbiota to low-molecular weight 
metabolites. Their subsequent tissue distribution is still undefined, though these microbial 
metabolites are currently believed to play a role in human health and disease states. 
 To fill this knowledge gap, we performed a pharmacokinetics experiment in which a 
single bolus of 23 polyphenol microbial metabolites (total 2.7 µmol) was administered 
intravenously to rats to reliably reproduce a physiological post-absorption situation. Tissues and 
urine were collected shortly thereafter (15 sec to 15 min) and were analyzed by UHPLC-MS/MS 
to quantitatively track these compounds. Remarkably, the brain was found to be a specific target 
organ for ten of the 23 polyphenol metabolites injected, which significantly increased in the 
treated animals. In most cases, their appearance in the brain was biphasic, with an early wave at 
2 min (4 compounds) and a second wave starting at 5 min; at 15 min, 9 compounds were still 
detectable. Most compounds were excreted into the urine. The concentrations in the brain of the 
treated animals were compared against those of the control group by Student’s t-test, with P-
values < 0.1 considered statistically significant.  
These findings provide new perspectives for understanding the role of diet on brain 
chemistry. Our experimental approach has enabled us to obtain rich metabolomics information 
from a single experiment involving a limited number of animals. 
 
 
Keywords polyphenols, gut microbiota, target metabolomics, mass spectrometry, brain, fruit 
consumption  
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 3 
 Introduction  
 
A diet rich in fruit and vegetables is regarded to be an important factor for protecting the 
human organism from chronic diseases.
1
 However, dietary recommendations require knowledge 
about food composition, identification of bioactive food components, characterization of 
bioavailability and tissue distribution, the elimination patterns of metabolites, and components’ 
specific effects on cellular homeostasis.  
Polyphenols, which are a wide and heterogeneous group of bioactive compounds found 
in vegetables and fruits
2
, especially berries
3
, are regarded to be responsible for protecting the 
human organism from oxidative stress-related chronic diseases. The bioactivity of polyphenols 
may serve a much broader purpose, however.  
After ingestion, only a minor part of the polyphenols (5-10%) is absorbed in the small 
intestine. The remainder reaches the colon, where it is extensively metabolized by gut microbiota 
to low-molecular weight compounds.
4
 Gut microbiota consist of many trillions of microbial 
cells
5
 whose metabolic activities have been shown to modulate human metabolic phenotypes
6–8
 
and thus play an essential role in human health. 
The microbiota break down dietary polyphenols through the actions of glucosidases, 
esterases, demethylases, dehydroxylases and decarboxylases
5,9–18
 to produce smaller common 
metabolites, such as phenolic acids and short-chain fatty acids
9
, collectively known as 
polyphenol microbial metabolites (PMMs). These are absorbed by the colonic epithelium and are 
found in the blood with patterns that correlate with the diet and individual microbial 
composition.
19
  
PMMs are regarded to be responsible for the health effects that correlate with regular 
berry fruit consumption.
4,20
 Epidemiological studies associate polyphenol consumption with 
reduced cancer and cardiovascular disease risk.
21,22
 Research on the neuroprotective effects and 
prevention of brain aging by dietary polyphenols has also increased in recent years.
22–28
 The 
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 4 
literature reports that diets rich in polyphenols attenuate neuropathology indicators and cognitive 
decline.
25
 Some studies report direct effects of polyphenols on intracellular targets, e.g., three 
members of the secretase family known to be involved in the amyloidal aggregation have been 
connected with the onset and progression of Alzheimer’s disease.
29
 The question of whether 
these compounds are able to pass the blood-brain barrier and achieve a pharmacologically 
relevant concentration there remains unanswered.  
The importance of microbiota for brain function development has been noted by 
numerous studies of experimental animals
30–32
, and these observations can be translated to a 
better understanding of human brain disorders. For instance, autism, a defect of brain 
development leading to impaired social interaction, is now understood to be linked to abnormal 
microbiota population and poor intake of fruits and vegetables.
33
 It might be speculated that 
PMMs are involved in normal neural development and function. Indeed, they are chemically 
identical or similar to catabolites of amino acids and neurotransmitters.  
It seems, however, that PMMs may have some yet uncharacterized bioactivity that has an 
impact on health.
20
 Current information concerning the absorption and distribution of PMMs in 
mammalian tissues is still poor
9,34
 and not substantial enough to support the hypothesis that 
PMMs are the bioactive agents of our diet. Therefore, it is not possible to make dietary 
recommendations for early prevention of brain dysfunctions. 
Given this background, the focus of this study was to examine the ability of selected, 
unconjugated PMMs to enter the brain relative to the main excretory organs. Therefore, we 
performed an experiment to assess the time-dependent tissue distribution of a single intravenous 
injection of a PMM mixture in anaesthetized rats.  
The superior selectivity, sensitivity and dynamic range of modern tandem mass-
spectrometry enabled us to harvest data on a wide range of diverse PMMs in a single in-vivo 
experiment. It is noteworthy that our experimental strategy involved the least number of animals, 
in compliance with the 3R principles on animal experimentation.   
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 5 
The data obtained show for the first time the simultaneous quantitative profile of several 
PMMs in a mammalian system, proving their distribution in the brain, the main excretory organs 
(liver and kidneys), the heart, the blood and the urine. For some PMMs, specific tropisms were 
also observed, pinpointing target organs for future experimentation. Remarkably, the data 
obtained show that at least 10 PMMs incrementally appear in the brain within 15 min, whereas 
they simultaneously disappear from the blood and/or reach other organs. 
 
 
Results and Discussion 
 
The tested mixture of polyphenol microbial metabolites: a rational choice 
The strategy was to simultaneously inject 23 metabolites in a well-defined mixture into a 
single animal (Figure 1).  
The selected metabolites are known products of the gut-microbiota metabolism of 
polyphenols found in berries.
11–13,17,35
 Their individual concentrations in the mixture were chosen 
to mimic their average plasma concentration measured after the intake of a berry fruit serving.
36
 
All individual molecules were commercially available except for urolithin A and B. The latter 
are regarded to be specific biomarkers of dietary ellagitannins metabolized by gut microbiota and 
were synthesized in-house.
37  
  
An analytical method based on UHPLC-MS/MS enabled quantitative measurements of 
this set of 23 compounds in biological fluids and tissue extracts from a single rat,
38
 resulting in a 
remarkable reduction in the number of experimental animals, as recommended by the regulatory 
bodies.
39
  
The in vivo injection of a multi-component mixture could give rise to potential problems. 
Some metabolic pathways could transform certain metabolites into other compounds already 
present in the mixture, thus altering the chemical composition of the injected mixture. The 
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 6 
simultaneous injection of different metabolites could also affect the rate of membrane transport, 
enzyme pathways or cellular regulatory mechanisms, resulting in competitive interactions, rapid 
states of saturation or cooperative responses, to name a few. However, this was a physiological 
situation, closely simulating a nutritionally relevant scenario in the blood. Analyzing a multi-
component mixture made it possible to simultaneously follow the tissue distribution of each 
compound, especially with respect to the brain, whereas the presence of other congeners or 
further metabolites (e.g., glucuronides or sulfates) could not be followed.  
 
Dosage, administration route and time-line: a strategy for accurate tissue distribution 
analysis  
The most accurate approach for a study on PMM tissue distribution is to administer the 
PMMs by intravenous injection, thereby minimizing the main factors of inter-individual 
variability in gut metabolism, motility and absorption.
6
 Any other downstream processes, such as 
distribution into tissues and mammalian phase-1 and phase-2 metabolism, are comparatively 
more homogenous among individuals.
40
 As a consequence, a satisfactory variation coefficient 
was obtained for all measured parameters, using the least number of animals (n=4 in this study). 
The injected dose was 2.7 µmol, which was the sum of 23 individual PMM amounts 
(Figure 1) from 0.9 µmol (gallic acid) to 0.0005 µmol (sinapic acid). Considering that the rats 
(body mass=288±20 g) had an estimated blood volume of 16 mL41 and assuming that all of the 
mixture components had free access to the internal volume of blood cells, the initial blood 
concentration was 168 µM, which spanned from 56.25 µM (gallic acid) to 0.31 µM (sinapic 
acid). These values are within the concentration range observed in humans following the 
consumption of a standard serving of berry fruits.
42
 
The experiment was designed on the basis of previous data showing the exceptionally 
fast uptake and metabolism of a dietary flavonoid, i.e., cyanidin 3-glucoside, a ubiquitous 
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 7 
pigment in red fruits.
40
 It was assumed that the plasma disappearance kinetics of low-molecular 
weight flavonoid metabolites and other dietary polyphenols should follow a similar pattern. 
The site for the intravenous PMM mix injection was the dorsal penis vein, which is easily 
accessible through a thin epidermal layer and is afferent to the general circulation.
43
 Minimally 
manipulating an anaesthetized animal is seen as a crucial factor because any inflammation 
mediator that is locally released following surgical trauma might affect the permeability of the 
blood-brain barrier and/or the basal functions that determine distribution and excretion (i.e., 
membrane transporters) or metabolism (i.e., enzymes). 
The time points chosen were seemed appropriate for the time course, both in terms of the 
injected molecules’ disappearance from the blood and their appearance in the organs and urine. 
Under the chosen conditions, the animals were under minimal duration of anesthesia and 
physical stress. Overall, this experiment is a refinement of previous protocols that we have 
used.
40,44
 
 
The presence of basal levels of the mixture components in control animals  
Many of the mixture components arise not only from the microbial metabolism of dietary 
polyphenols but also from mammalian catabolism of endogenous substrates.
36
 Thus, some were 
expected to occur in the rat organs and fluids at basal levels in control animals. Compounds that 
are exclusively products of microbial metabolism are the urolithins, ferulic acid, gallic acid, 
coumaric acid and protocatechuic acid.
36
 However, these might also be expected to occur in 
control animals as they are markers of normal nutritional status (e.g., ferulic acid). The basal 
levels of the 23 component mixture were very low in general. Exceptions are mentioned case by 
case below. 
 
Tracing polyphenol metabolites in blood 
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 8 
The blood of control rats contained 11 of the 23 injected molecules. Of these endogenous 
compounds (Table 1), six were found at less than 1% of the amount occurring in the injected 
mixture, and another 3 were found at less than 2%. The 2 outliers were p-coumaric acid (3.3%) 
and phloroglucinol (17.8%). Thus, the selected mixture represented a valid challenge for a 
pharmacokinetic test because of the low basal levels. This test seemed to reliably simulate what 
happens in the organism after consumption of a standard berry fruit serving after a short “wash 
out” period. 
Most injected compounds disappeared following apparent pseudo-first order kinetics, as 
shown in Figure 2. The calculated parameters, i.e., the extrapolated amounts at time zero (t0) and 
at steady state (t∞), and the disappearance rate constant (ke), which spanned from 2.73 to 0.38 
min
-1
 (t/2=0.25 to 1.84 min) and pointed to a rapid process, are shown in Table 1. The recovery 
in blood extrapolated at t0 was within 8.5 and 43.5% for 17 of the 23 metabolites (Table 1), 
showing that a major fraction of these compounds was not easily extractable from the whole 
blood. The formation of complexes with the serum proteins therefore still left a significant 
concentration of the unbound form; for the majority of the studied metabolites: this is expected 
to be the active form, which undergoes metabolism and reaches the tissues. However, there were 
a few exceptions.  
Pyrogallol could never be detected, though its recovery and analysis posed no specific 
issues; the mechanisms of its disappearance were unknown. Two compounds, pyrocathecol and 
3,4-dihydroxyphenyl acetic acid, were detected only at 15 sec. Urolithin B was detected at very 
low levels at both 15 sec and 2 min and rose thereafter by an order of magnitude. Phloroglucinol 
occurred at a similar level during the entire experiment. Gallic and caffeic acid showed a very 
modest recovery, indicating a very modest presence in the free form in the bloodstream. 
With the few exceptions mentioned above, steady state values were attained even earlier 
than 5 min; therefore, the duration of the experiment was appropriate. In most cases, the 
compounds were essentially disappeared at 15 min. 
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 9 
The calculated amounts at t0 and at any time point were always lower than the sum of the 
injected dose and any endogenous compounds in the control samples. The calculated t0 amounts 
ranged from 43.5% (m-coumaric acid) to 1% (gallic acid) and were expressed as a percentage of 
the injected amounts as shown in Table 1. This result is not surprising given the fast uptake and 
excretion of one precursor of these metabolites, i.e., the fruit pigment cyanidin 3-glucoside.
40
  
An explanation for the loss of part of the injected dose and for the extremely rapid blood 
disappearance may be quick uptake and distribution to the organs. Only some major organs were 
collected, so a cumulative recovery assessment could not be provided. The compounds also 
might have been distributed in the large tissues, such as adipose, vascular endothelium or 
connective tissues. The administered compounds could also have been metabolically 
transformed, but these were not analyzed in this experiment. This is the first attempt at a 
simultaneous kinetic characterization of 23 polyphenol metabolites. 
  
Polyphenol microbial metabolites in the brain 
The main findings concerned the detection of PMMs in the brain at times when their 
blood concentrations were vanishingly low (Figure 3). Each plot shows 2 curves representing the 
total amounts measured in whole brain (dotted line) and those corrected for residual blood 
(continuous line), as recommended.
45–48
 Indeed, the brains were not perfused to wash out the 
blood because this procedure would have altered the chemical equilibrium between the vascular 
compartment and the whole brain.  
Thirteen of the 23 compounds in the mixture were found in the control brains as 
endogenous metabolites (Table 2). Disregarding the observation time, 10 of the 23 compounds 
were found in the brain at a significantly increased amount with respect to the controls (Table 2). 
In most cases, their appearance in the brain was biphasic, with an early wave at 2 min, as 
observed with 4 compounds and a second wave starting at 5 min. Nine compounds were detected 
at 15 min. Gallic acid, which was the most abundant compound in the mixture (Figure 2), best 
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showed this bi-phasic accumulation trend. It is noteworthy that the gallic acid accumulated in the 
brain at approximately 11 times the basal concentration measured in the controls at as early as 15 
sec. Similarly, caffeic acid had two peaks at 2 and 15 min and accumulated by approximately 20 
and 34 times, respectively (Table 2).  
Importantly, two compounds (trans-isoferulic acid and o-coumaric acid) were not 
detected in the brain as endogenous metabolites nor did they ever appear in the brain despite 
their relatively low plasma elimination rate constant. This proved that the blood-brain barrier was 
intact during the experiment. Endogenous compounds protocatechuic acid and phloroglucinol 
never had an increased concentration in the brain. 
The compounds that accumulated in the brain should be active because, in all cases 
except urolithin B, they were endogenous metabolites already present in the control brains. Their 
most predictable effect is unbalancing a pre-existing metabolic equilibrium. Ferulic acid, which 
accumulated by 15 sec in the experiment, is reportedly able to reduce oxidative damage and 
amyloid pathology in Alzheimer’s disease.
49
 Some PMMs are identical to neurotransmitter 
metabolites. For instance, vanillic acid and homovanillic acid are catecholamine catabolites that 
are found in the brain and in cerebrospinal fluid.
50
 Moreover, 3,4-dihydroxyphenyl acetic acid 
(DOPAC) is a neuronal metabolite of dopamine (via monoamine oxidase) and a direct precursor 
of homovanillic acid. DOPAC is involved in dopamine catabolism in the pathogenesis of 
Parkinson's disease.
51,52
 Another mechanism of action involves the enzyme kinetics. Caffeic 
acid, for example, may bind to tyrosine ammonia lyase, thus altering serotonin homeostasis
53
, or 
it may inhibit acetylcholinesterase and butyrylcholinesterase activities, thereby preventing 
oxidative stress-induced neurodegeneration.
54
 Gallic acid has also been shown to act on key 
enzyme processes in the brain
26,55
 and can accumulate in the brain after repeated doses.
56
 
 
Polyphenol microbial metabolites in other organs 
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The analyses of PMMs in the heart, the liver, the kidneys, and the urine are shown in 
Figure 5 (and in supplementary Figures 1-4). Eighteen of the 22 compounds attained very high 
concentrations in the urine (Figure 4, supplementary Figure 1). The exceptions were 
pyrocatechol and urolithin B, which were not found in the urine; urolithin A, the concentration of 
which slightly increased; and phloroglucinol, which did not change with respect to the value 
found in control animals. Thus, most PMMs can be defined as nephrotropic. Indeed, 20 of the 22 
compounds dramatically increased their parenchymal concentrations from basal values 
approximately zero up to at least 2 orders of magnitude higher (Figure 4, Supplementary Figure 
2). Due to this extraordinary speed, the apparent rate of accumulation in the kidneys could not be 
calculated. Accumulation lasted no more than 2 min and often less, after which time the 
concentration started to decay. In contrast, the appearance in the urine was slower, with a lag 
phase lasting 15 sec before the onset of urinary excretion in most cases (20 out of 22).  
Only a few compounds were found to be hepato- rather than nephrotropic, including 
phloroglucinol, urolithin A and 4-hydroxybenzoic acid (Figure 4, Supplementary Figure 3). One 
compound (sinapic acid) could not be detected in the liver for 3 consecutive sampling times even 
though it was present in the blood. Therefore, the amount of blood retained in the organ was 
negligible. Similarly, the basal levels of 3-(3-hydroxyphenyl) propanoic acid did not change in 
the liver, despite its presence in the blood at a 2 orders of magnitude higher concentration.  
Only 3 compounds were found to be cardiotropic, i.e., vanillic acid and both urolithins 
(Figure 4, Supplementary Figure 4). They accumulated to a maximum concentration at 15 sec, 
after which vanillic acid and urolithin A disappeared, whereas urolithin B started to increase 
again at 5 min. Three compounds (phloroglucinol, 3,4-dihydroxyphenyl acetic acid and 
pyrocatechol), though present in the blood, could not be detected in the heart, demonstrating 
negligible blood contamination during the tissue extraction. 
The low apparent hepatotropism of most PMMs leads to the conclusion that PMMs 
absorbed from the colon under normal conditions undergo limited first-pass metabolism into the 
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liver so that they can be distributed to the other organs readily after absorption. They are then 
eliminated in the urine after prior accumulation in the kidneys. Only one compound, 4-
hydroxybenzoic acid, appeared in the urine at 15 sec, likely by glomerular filtration. 
 
The case of urolithins 
Urolithins, with MWs ranging from 212-228 Daltons, are the largest PMM molecules 
(Figure 1) and arise from the microbial metabolism of ellagitannins and ellagic acid conjugates.
57
 
Urolithin A differs from urolithin B by one additional hydroxyl group. No other mammalian 
enzyme pathway is known to produce such end products from more complex precursors. No 
urolithins were detected in the organs of the control animals. Urolithin A and B were 
administered at different doses, i.e., 55 and 25 nmol, respectively. Nevertheless, their 
concentrations in the blood differed by an order of magnitude at 15 sec (332.6 and 20.3 
pmol/mL, respectively). Thus, urolithin B was sequestered (and/or metabolized) more rapidly 
than urolithin  A in the tissues.  
Both urolithins displayed a unique blood concentration pattern, tissue distribution and 
urinary excretion (Figure 6). Indeed, though urolithin A had a normal mono-exponential 
disappearance from the blood, urolithin B increased in the blood after 2 min from a very low 
level (see above). Therefore, it seems that urolithin A underwent a very unusual and 
mechanistically unexplained de-hydroxylation reaction. Only bacterial de-hydroxylases are 
known. 
Both urolithins were negligibly excreted in the urine, which is unique among the PMMs. 
They were presumably excreted as glucuronyl derivatives
11
, which were not analyzed. Rapid 
uptake of urolithin A into the kidneys was observed, whereas urolithin B appeared in the kidneys 
only after 2 min when it was also present in the blood. The liver slowly absorbed urolithin A up 
to 5 min, but no urolithin B could be detected in the liver at 15 min. This shows that the liver 
could neither convert urolithin A to urolithin B nor take the latter up from the blood. 
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The organ that displayed the highest uptake capacity was the heart, where both urolithin 
A and B were found at 15 sec, at approximately 300 and 2000 pmol/g, respectively. It seems 
likely that the following occurred: i) urolithin A was rapidly (by 15 sec) taken up into the heart 
and de-hydroxylated to urolithin B by an unknown enzyme(s) or in the heart both urolithins 
could be converted to other compounds that were not followed; ii) urolithin B was released from 
the heart into the blood, where it increased from 2 to 5 min; iii) from 5 min on, the urolithin B 
tissue concentrations increased at higher levels than in the blood. 
 Urolithins have a demonstrated activity of reducing protein glycation
58
 in neuronal cells 
and possibly even in the heart. In fact, the advanced glycation end products, derived from the 
glycation reaction in the heart and vascular tissue, are responsible for a reduction in artery and 
heart elasticity and have a role in the progression of cardiovascular complications associated 
with diabetes.
59
  
 
Is the brain a target of polyphenol metabolites? 
The findings would suggest so. To our knowledge, ours is the first report showing that no 
less than 13 PMMs were found at basal levels in control brains. As a consequence, the possibility 
of their passage through the blood-brain barrier must be assumed a priori to ensure exchange 
with the blood compartment.  
Ten of the 23 compounds were found to be significantly increased after injecting the 
PMM mixture into the animals. Some of the compounds could have a strictly dietary origin, such 
as gallic acid or trans-ferulic acid, whereas others could be catabolites of endogenous 
compounds, such as catecholamine, dopamine, amino acids and others. Figure 6 highlights the 
gallic acid concentration attained in all of the organs considered at various times. The brain 
clearly had the capacity to extract gallic acid from the blood, even higher than that of the liver. 
On the other hand the tightness of the blood-brain barrier is demonstrated by its absolute 
impermeability to o-coumaric acid, in spite of its higher hydrophobic index (logP: 2.45, while 
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gallic acid logP is 0.91). However, both gallic acid and o-coumaric acid have similar 
concentrations in the blood.  
These data suggest that there are further health implications for the brain-gut microbiota 
axis
54
 and highlight how PMMs could be players in the putative connections/messengers 
between the microbiota and brain. These bidirectional interactions have already been explored 
and highlight the importance of the gut microbiota for brain development and behavior
55
, as well 
as for their influence on anxiety and depression.
56
 Because PMMs are the product of dietary 
polyphenol intake and metabolism by the gut microbiota, it is reasonable to assume that these 
compounds might be able to regulate human health and disease states.
57
 Moreover, the role of 
gut microbiota in the alteration of mammalian blood metabolite levels has already been 
demonstrated through combining data from germ-free and conventional animals.
58
 Their action 
may be related to oxidative stress control or, more likely, to the modulation of biochemical and 
physiological processes by changing the level of endogenous compounds in the brain and other 
organs, as observed in the present study. 
 
 
Methods  
 
Chemicals  
Phloroglucinol, pyrogallol, gallic acid, protocatechuic acid, 3,4-dihydroxyphenylacetic acid, 4-
hydroxyhippuric acid, 4-hydroxybenzoic acid, pyrocatechol, caffeic acid, vanillic acid, 3-
hydroxyphenylacetic acid, homovanillic acid, 3-(4-hydroxyphenyl) propanoic acid, 3-(3-
hydroxyphenyl)propanoic acid, hydroferulic acid, trans-ferulic acid, trans-isoferulic acid, sinapic 
acid, m-coumaric acid, o-coumaric acid and p-coumaric were purchased from Sigma-Aldrich 
(Saint Luis, Milan, Italy). The isotopically labeled compounds, butyric acid-d7 and cinnamic 
acid-d5, were used as internal standards and purchased from C/D/N Isotopes Inc. (Quebec, 
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Canada). Urolithin A and urolithin B were synthesized following a published protocol
37
 and were 
characterized by NMR for structure confirmation and purity. LC/MS formic acid, Chromasolv 
LC/MS methanol and acetonitrile were purchased from Sigma-Aldrich. 
 
Study design  
The experiment was designed as a multi-component pharmacokinetic study with 
quantitative analysis of organs (liver, kidney, heart and brain) and biofluids (blood and urine). 
The aim was to explore the fate of a polyphenol microbial metabolite mixture in a mammalian 
system after entering the bloodstream. The experiment was divided into four time points: 15 sec, 
2 min, 5 min and 15 min. Each time point was represented by 4 replicates. Four rats received the 
polyphenol microbial metabolite dose, whereas one blank rat served as a control without the 
polyphenol metabolite mixture but with an identical experimental procedure. The control animals 
that were not injected with the polyphenol microbial metabolites could also be considered as 4 
control replicates to compare at each time point. The short kinetics trial time did not have an 
effect on the concentration and endogenous metabolite pattern in the control animals. 
Twenty male rats (Rattus norvegicus, Wistar, Harlan Italy S.r.l.) were bred in the animal 
facility at the University of Trieste. The experiment was approved by the bioethical committee of 
the University of Trieste (doc. 865PAS12). Animal experiments were carried out in compliance 
with the provisions of the European Community Council Directive.
39
 Rats (n=20) at the same 
age (12 weeks) and weight (288 ± 20 g) were maintained in temperature-controlled rooms at 22-
24 °C, 50-60% humidity and 12 hour light/dark cycles. They were fed until the night before the 
experiment with standard laboratory chow. 
During the in vivo experiment, the rats were kept under quiet conditions. The cages were 
covered with cloth so that they were either sleeping before the anesthetic injections or were 
awake but without apparent nervous behavior. After the anesthetic, the animals were left alone to 
fall asleep in another covered cage. In all cases, the animals’ conditions were monitored.  
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Polyphenol microbial metabolite mixture for intravenous (i.v.) administration 
The polyphenol metabolite mixture comprised 23 low-molecular-weight (110-228 
Daltons) metabolites, which were selected from the key polyphenol metabolism products by gut 
microbiota after the consumption of berry fruits. The metabolites and dosages were selected from 
reports in the literature. Each metabolite was dissolved in methanol and then mixed together 
according to the various selected amounts.  
 
Treatment of rats  
The rats were divided into two groups for a two-day experiment, with 2 pharmacokinetic 
time points per day. On the first day, time points 15 min and 2 min were chosen. Time points 5 
min and 15 sec were performed on the second day. On the night before the experiment, the rats 
(10 animals) were starved overnight but were provided with water ad libitum. They were divided 
into 5 different cages for the experiment. 
The rats were anaesthetized with intra-peritoneal administration of Tiletamine/Zolazepam 
(1:1, 25 mg/kg body weight) and Xylazine (10 mg/kg body weight). Each rat received an i.v. 
administration of 0.3 mL PBS (phosphate buffer solution) containing 2.7 µmol of polyphenol 
metabolite mixture, dissolved in 30 µL methanol. The blank control animals received an i.v. 
injection of 0.3 mL PBS with 30 µL methanol.  
During anesthesia (10 min) the heart and ventilation rates were controlled. The rats were 
placed on their backs and the penis was extruded by sliding the prepuce downwards. With the 
use of a nipper, the glans penis was held at the tip. The dorsal penis vein was then visible and at 
exactly 10 min after anesthesia, 0.3 mL PBS with (treated) or without (blank) 2.7 µmol 
polyphenol metabolite mixture was injected using an insulin syringe. The injection site was then 
pressed for a few seconds and the glans was retracted to prevent bleeding.
43 
One min before the 
rat was sacrificed, sodium heparin (0.1 mL, 500 IU) was injected again into the dorsal penis vein 
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as before. For time point 15 sec, the procedure was slightly different: after 10 min of anaesthesia, 
0.2 mL PBS and 0.1 mL sodium heparin with (treated) or without (blank) 2.7 µmol polyphenol 
metabolite mixture were simultaneously injected using an insulin syringe. 
The rats were sacrificed by decapitation. Blood was drained from the body and urine was 
collected through the urinary bladder with a syringe. The liver, kidney, heart and brain were 
excised from the body, washed with Milli-Q water and immediately frozen in liquid nitrogen and 
stored at -80 °C. 
 
Organ collection and extract preparation  
 
Extraction from blood and urine 
After sampling, an aliquot of blood (5 mL) was transferred into aqueous methanol (95:5, 
v/v) at a ratio of 1:9 (v/v). The internal standard cinnamic acid-d5 was dissolved in aqueous 
methanol at a concentration of 100 mg/L for monitoring the extraction protocol. The sample was 
shacked and extracted for 10 min. The extract was then centrifuged for 5 min at 3600 rpm at 4 
°C. The blood extract with the buoyant (non-cellular) portion was transferred to 50 mL dark 
glass vessels and stored at -80 °C.
44
 The choice of extracting blood instead of plasma or serum 
was made to eliminate the need for a centrifugation or blood-clotting step, during which 
metabolic changes might have occurred ex vivo.
 60
 
In the same way, an aliquot of urine was collected with a syringe and extracted with 
aqueous methanol (95:5, v/v). The urine was weighed and the amount of solvent for extraction 
was adjusted to a 1:9 ratio (w/v).  
 
Tissues  
Organs that were frozen in liquid nitrogen immediately after excision were stored at -80 
°C. Frozen liver, kidney, heart and brain were ground under cryogenic conditions using liquid 
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nitrogen with a CryoMill (Retsch, Germany) and a single 25-mm i.d. steel ball (30 sec. with a 
frequency of 25/sec.). Tissue powder (1 g) was transferred (without thawing) into aqueous 
methanol (5:95 v/v) at a ratio of 1:9 (w/v). The internal standard cinnamic acid-d5 was dissolved 
in the aqueous methanol at a concentration of 100 mg/L to monitor the extraction protocol. The 
samples were extracted on an orbital shaker for 10 min, then centrifuged and decanted as 
described for blood. The final volume was then adjusted to 10 mL to balance any possible 
variation in the amount of water among the organs and stored at -80 °C.  
 
Solid Phase Extraction (SPE) purification and sample preparation  
 
The SPE protocol was applied following a procedure developed by Passamonti et al.
61
 
with modifications as reported by Gasperotti et al.
38
 The cartridges used for the SPE purification 
were Biotage Isolute ENV+, 1 g (Uppsala Sweden).  
The internal standard butyric acid-d7 was dissolved in methanol/water (50:50 v/v) at a 
concentration of 1 mg/L and added to the sample to monitor the quantitative recovery during 
sample reconstitution.  
 
Targeted metabolomics analysis by UHPLC-ESI-MS/MS 
A targeted metabolomics analysis was performed with an ultra-performance liquid 
chromatographic system (UHPLC) coupled to a tandem mass spectrometer. The system used was 
an ACQUITY UPLC system coupled to a Xevo TQ triple quadrupole via an electrospray (ESI) 
interface (Waters, Milford, Massachusetts, USA). The separation of the 23 target metabolites and 
2 deuterated internal standards was performed with a Waters ACQUITY UPLC column and HSS 
T3 (100 mm x 2.1 mm, 1.8 µm) equipped with a guard column. The injection volume was 10 µL. 
Mobile phases of 0.1% formic acid in Milli-Q water (A) and 0.1% formic acid in acetonitrile (B) 
were used. Chromatographic separation was performed using a gradient as follows: 0 min, 5% B; 
Page 18 of 33
ACS Paragon Plus Environment
ACS Chemical Neuroscience
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 19 
0-3 min, 5%-20% B; 3-4.30 min, 20% B; 4.30-9 min, 20%-45% B; 9-11 min, 45%-100% B; 11-
14 min, 100% B; and 14.01-17 min, 5% B as equilibration time. For calibration, a standard 
mixture of polyphenol metabolites was serially diluted in aqueous methanol (50:50) at a 
concentration range of 0.01 µg/L - 100 mg/L. Quantitative data were processed with Targetlynx 
software (Masslynx, Waters).  
Details of the UHPLC-ESI-MS/MS method and quantification are described in Gasperotti et al.
38
 
 
Blood residual subtraction for the brain samples 
The concentrations in the rat brain may be significantly influenced by the quantities of 
metabolites in the residual blood. The correction was made by estimating the amount of 
metabolites in the intravascular blood present in the brain, assuming that the volume of brain 
blood is 47.7 µL/g.
46
 We then subtracted this from the total amount found in the brain. The 
results of this subtraction are presented in Figure 3, which also compares the data of the brain 
before the blood residual subtraction. 
 
Calculation of pharmacokinetics parameters 
Pharmacokinetic parameters were calculated using GraphPad Prism 5 (GraphPad Software, La 
Jolla, CA, USA) with a one-phase decay function suitable for i.v. injection experiments. The 
extrapolated dose at time 0 (t0) and the dose at steady state (t∞) were obtained from the plotted 
curves for each metabolite detected and quantified in the blood. The area under the curve (AUC 
0

15 min.) and the elimination rate (Ke) were also obtained from the plotted curves. 
 
Statistical analysis 
The quantitative data for the PMM levels are presented as the mean values ± standard error (n = 
4) for all of the graphs. The concentrations in the brain of the treated animals were compared 
against those of the controls using Student’s t-test, with P-values < 0.1 considered statistically 
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significant. Relaxing the significance threshold to 0.1 enabled us to identify the most potentially 
relevant information and minimize type II error in these experiments while involving the least 
number of animals, in compliance with the legislation regulating the use of animals in scientific 
procedures. 
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Figure 1: Mixture of polyphenol microbial metabolites used for the intravenous injection, their 
chemical formula, molecular weight (MW), dose and relative percentage on the total amount 
injected, 2690 nmol (dosage:168.13 µM)  
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 Figure 2: Kinetics of distribution of polyphenol microbial metabolites in blood. 
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Figure 3: Kinetics of distribution of polyphenol microbial metabolites in brain. Dotted lines are 
referred to the amount found in the whole brain, while continuous lines are the data after the 
subtraction of the blood residual in the brain. Data with the asterisk are significantly increased 
from the control samples (p < 0.01***, p < 0.05**, p < 0.1*). 
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Figure 4: Kinetics of distribution of polyphenol microbial metabolites in liver, kidney, urine and 
heart. Legend of the symbols is reported in the first graph. 
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Figure 5: Kinetics of distribution of gallic acid and o-coumaric acid in brain, liver, kidneys and 
blood. 
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Figure 6: Kinetics of distribution of urolithin A and B in all the organs considered for the 
experiment. 
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Table 1: Percentage of recovery in blood compared to initial injected dose and pharmocokinetic analysis of polyphenol microbial metabolites 
(dose at the steady state (t=∞), area under the curve (AUC 015) and elimination rate (Ke)). For the recovery the values given are the percentages of 
dose found in rats after the i.v injection at four different time points (t0.25, t2 ,t5, t15 min.) and control, sd is the standard deviation of 4 replicates. For 
t0 the percentage reported is an extrapolation based upon the pharmacokinetics curves associate to a first order exponential decay for an i.v 
injection.  
     Time Points (min.)  Pharmacokinetics 
 
dose t0 * t0.25 t2 t5 t15 Control 
 
Steady 
state t=∞ 
AUC   
(0 →15) 
k e 
  
nmol % average recovery % ± st. dev. 
  
pmol/m
L 
pmol*
min/m
L 
min-
1 
4-hydroxyhippuric acid 250 13.3 11.7 5.5 13.4 6.2 6.4 6.1 2.4 0.6 0.0 0.0  0.00 15017 0.09 
3-hydroxyphenylacetic acid 150 19.9 18.6 6.2 10.5 2.7 6.5 1.5 3.0 1.6 0.6 0.2  304.50 9238 0.38 
homovanillic acid 50 18.7 17.5 5.2 8.8 0.8 7.0 1.7 3.0 1.2 0.4 0.3  118.40 3022 0.45 
o-coumaric acid 15 34.6 32.0 11.1 15.7 2.3 12.1 2.8 5.2 2.3 0.1 0.1  62.70 1597 0.47 
trans-isoferulic acid 35 25.9 23.2 7.1 9.3 1.8 7.0 2.3 1.9 1.0 0.0 0.0  73.40 2125 0.58 
4-hydroxybenzoic acid 100 18.5 16.3 5.3 6.5 0.6 3.8 1.5 1.5 0.4 1.7 0.9  131.50 3864 0.62 
vanillic acid 50 18.7 16.3 7.6 6.4 1.8 3.9 1.5 1.8 0.4 1.3 0.5  75.70 1992 0.67 
3-(4-hydroxyphenyl)propanoic acid 100 24.8 21.9 6.4 10.1 1.0 8.4 2.2 4.6 1.1 0.4 0.5  371.50 7538 0.69 
urolithin A 55 11.5 9.7 3.3 2.9 0.9 0.8 0.1 0.1 0.1 0.0 0.0  9.80 733 0.71 
3-(3-hydroxyphenyl)propanoic acid 450 15.5 13.5 3.6 5.7 0.8 5.1 0.8 2.2 0.6 0.8 0.6  929.30 19569 0.72 
p-coumaric acid 15 22.2 19.3 5.0 7.9 1.3 6.6 1.3 3.0 1.1 3.3 5.4  40.50 872 0.74 
trans-ferulic acid 60 18.0 14.7 5.9 3.8 0.5 1.9 0.7 0.5 0.5 0.0 0.1  39.30 1387 0.88 
caffeic acid 60 1.8 1.4 0.5 0.3 0.0 0.1 0.1 0.0 0.1 0.0 0.0  2.53 108 0.95 
sinapic acid 5 14.5 11.6 4.8 2.8 0.3 1.2 0.1 0.6 0.7 0.0 0.0  2.40 84 0.95 
hydroferulic acid 75 19.3 15.7 5.7 4.6 0.4 3.6 1.2 1.2 0.7 0.1 0.1  105.30 2535 0.96 
m-coumaric acid 15 43.5 35.1 12.6 9.8 1.5 6.8 2.9 2.7 1.8 0.0 0.0  41.60 1044 0.97 
protocatechuic acid 65 8.5 6.6 1.2 3.3 0.5 4.0 3.9 2.4 0.7 1.4 0.1  129.70 2101 1.72 
gallic acid 900 1.0 0.6 0.5 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.0  72.40 1296 2.73 
phloroglucinol  100 26.3 23.0 5.8 26.2 4.1 22.8 10.8 17.7 9.8 17.0 6.7  § 19951 § 
3,4-dihydroxyphenyl acetic acid 75 § 0.3 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0  § 13 § 
pyrocatechol 15 § 1.0 0.9 1.2 2.4 0.0 0.0 0.0 0.0 0.0 0.0   § 35 § 
urolithin B 25 § 1.3 1.0 0.4 0.2 9.4 4.2 9.3 12.4 0.0 0.0  § 1721 § 
 
* extrapolated value from the pharmacokinetic curves for the dose at time zero. 
§ no available extrapolated data due to the non fitting with the proper pharmacokinetic curves 
associated to an i.v. injection.  
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Table 2: Endogenous amounts of polyphenol metabolites in control brain and polyphenol 
metabolites significantly increased compared to control brain at any time points (p>0.1). 
 
 
dose
* 
control t0.25 t2 t5 t15 
fold of 
change 
t2/control 
fold of 
change 
t15/control 
  
pmol
/g of 
anim
al pmol/g   
4-hydroxyhippuric acid 868 5.52    20.06  3.63 
3-hydroxyphenylacetic acid 521 n.d.       
homovanillic acid 174 314.81    433.16  1.38 
o-coumaric acid 52 n.d.       
isoferulic acid 121 n.d.       
4-hydroxybenzoic acid 347 126.63  206.97  407.92 1.63 3.22 
vanillic acid 174 99.71    384.71  3.86 
3-(4-hydroxyphenyl)propanoic acid 347 3.88       
urolithin A 191 9.72       
3-(3-hydroxyphenyl)propanoic acid 1562 119.01    192.81  1.62 
p-coumaric acid 52 18.34       
trans-ferulic acid 208 6.34  27.01   4.26  
caffeic acid 208 0.11  2.36  3.81 21.45 34.64 
sinapic acid 17 n.d.       
hydroferulic acid 260 n.d.       
m-coumaric acid 52 n.d.       
protocatechuic acid 226 183.40       
gallic acid 3125 52.17 573.00 612.72 265.97 610.82 11.74 11.71 
phloroglucinol  347 1373.36       
3,4-dihydroxyphenyl acetic acid 260 291.82    501.19  1.72 
pyrocatechol 52 n.d.       
urolithin B 87 n.d.     2.09 2.50  > 2.50 
         
compounds increased at any time (p>0.1)   1 4 2 9   
 
* the dose is expressed as pmol/g of animal considering the rat average weight (288 g) for 
comparison with the amounts accumulated in rats  
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